Short, W. R., Koenig, S., Tebas, P., Gandhi, M. Are screening periods in ART-naive trials justified in the era of rapid ART? , Lancet HIV: 2026
Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., MacBrayne, C., Nakamura, M. M., Oliveira, C. R., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Willis, Z., Wolf, J., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab , Clin Infect Dis: 2026
Orkin, C., Mngqibisa, R., Velez, J. D., Kumar, P., Braun, D. L., Carr, A., Bloch, M., Walmsley, S., Tebas, P., Yokomaku, Y., Diamond, T. L., Jackson, B., Eves, K., Grandhi, A., Fuszard, M., Klopfer, S. O., Stamm, L. M., Fox, M. C., Kim, J. Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial , Lancet, 407(10528): 2026,599-610
Tebas, P., Jadlowsky, J. K., Zhou, Y., Pampena, M. B., Leslie, G. J., Liu, N., Srivatsa, S., Maldini, C. R., Wang, J., Tsang, C. J., Mohamed, O., Romano, J., Haggarty, B., Plesa, G., Gaymon, A. L., Brennan, A. L., Veloso, E., Levine, B. L., Putt, M. E., Kulikovskaya, I., Gonzalez, V., Fraietta, J. A., Betts, M. R., Hoxie, J. A., Riley, J. L. Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor , Mol Ther, 34(3): 2026,1352-1366
Orkin C.M., Mngqibisa R., Velez J.D., Kumar P., Braun D., Carr A., Bloch M., Walmsley S., Tebas P., Calmy A.L., Fuszard M., Diamond T.L., Jackson B., Fox M.C., Kim J. Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase III Study , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 515: 2026
Vendrame E., Fichtenbaum C.J., Osiyemi O., Wiznia A., Gupta S., Brimhall D., Morse C., Slim J., Tebas P., Liu X., Zheng Y., Chakrabarti T., Cortese M., Workowski K., Kumar P. Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T-Cell Engager, in People With HIV , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 371: 2026
Choudhary M.C., Choi Y., Aga E., Bosch R.J., Silva de Assis T., Landais E., Reeves J.D., Petropoulos C.J., Montefiori D., Caskey M., Bar K.J., Smiley S., Tebas P. Stable HIV-1 Autologous and Heterologous Virus Neutralization on Suppressive ART , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 301: 2026
Tebas P., Patel A., Agnes J., Parzych E.M., Tsang C., Morales K., Fisher P.D., Francica J.R., Humeau L., Pallesen J., Leon P., Esser M., Smith T.R.F., Weiner D.B. Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 180: 2026
Cha R., Serebryannyy L., Sieczkarski S., Rupert C., Smith N.M., Venuto C.S., Ma Q., Morse G.D., Maenza J., Wagner Cardoso S., Tebas P., Mellors J.W., Belaunzaran Zamudio P., Arduino R.C., Crowell T.A. Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 491: 2026
DeStefanis T., Belinky F., Ko S.H., Coates E., Strom L., Happe M., Bar K.J., Tebas P., Boritz E., Lynch R. In Vivo Escape Pathways to VRC07-523LS and VRC01LS and Their Effects on CD4bs bNAb Susceptibility , 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 578: 2026
